GSK aims to shrink its consumer health PR roster; Merck accused of sunscreen overcharges; Bayer files for 4th Eylea use in EU;

> GlaxoSmithKline ($GSK) is reviewing its U.K. consumer health public relations accounts, aiming to cut down on the number of different agencies handling the products. Report

> Merck ($MRK) has been named in a proposed class-action suit claiming that the company overcharges for its Coppertone sunscreen products with SPFs of 55 and above, because they have "virtually identical" active ingredients as Coppertone products with a lower SPF. Report (reg. req.)

> Bayer asked European officials to approve a fourth indication for its injectable ophthalmology drug Eylea, as a treatment for visual impairment from macular edema caused by branch retinal vein occlusion. Report

> The physician drug compendium Epocrates topped the rankings of medical reference apps for smartphones for the fifth year in a row. Release

> AstraZeneca ($AZN) backed a series of videos to promote Mental Health America's latest awareness campaign. Report

> The FDA issued new guidance on distributing journal reprints, this time in relation to articles conveying new risk information. Report

> Sagent Pharmaceuticals made Crain's Chicago Business' list of fastest-growing companies in the region. Report

And Finally... AbbVie ($ABBV) unveiled results of a study of treatment adherence in patients with inflammatory disorders. Release

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?